Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275)
China
· Delayed Price · Currency is CNY 13.41
-0.16 (-1.18%)
Sep 10, 2024, 3:04 PM CST
Guilin Sanjin Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 342.73 | 421.3 | 329.53 | 343.72 | 277.02 | 392.14 | Upgrade
|
| Depreciation & Amortization | 107.72 | 111.52 | 114.83 | 106.72 | 80.27 | 90.69 | Upgrade
|
| Other Amortization | 11.77 | 13.21 | 9.21 | 6.27 | 2.12 | 1.85 | Upgrade
|
| Loss (Gain) From Sale of Assets | -8.54 | -1.67 | -31.24 | -15.12 | - | -1.1 | Upgrade
|
| Asset Writedown & Restructuring Costs | 9.45 | 0.16 | 1 | 7.74 | 1.71 | 1.03 | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.47 | -6.73 | -5.87 | -9.65 | 1.37 | 17.34 | Upgrade
|
| Provision & Write-off of Bad Debts | -5.63 | 0.01 | 3.91 | 1.28 | -2.78 | 1.1 | Upgrade
|
| Other Operating Activities | 7.91 | 16.73 | 8.71 | 18.05 | -1.81 | -12.4 | Upgrade
|
| Change in Accounts Receivable | -88.27 | 72.95 | -88.25 | -66.83 | 108.49 | 93.44 | Upgrade
|
| Change in Inventory | -5.07 | -27.23 | 33.67 | -99.73 | -18.43 | -28.01 | Upgrade
|
| Change in Accounts Payable | 173.21 | -80.35 | 84.98 | 120.16 | 148.37 | -91.7 | Upgrade
|
| Change in Other Net Operating Assets | 27.17 | 30.48 | 65.78 | - | - | - | Upgrade
|
| Operating Cash Flow | 562.82 | 549.25 | 528.67 | 410.24 | 597.99 | 468.29 | Upgrade
|
| Operating Cash Flow Growth | 10.57% | 3.89% | 28.87% | -31.40% | 27.70% | -15.12% | Upgrade
|
| Capital Expenditures | -63.35 | -76.4 | -62.27 | -144.09 | -205.47 | -226.14 | Upgrade
|
| Sale of Property, Plant & Equipment | 56.63 | 53.69 | 2.75 | 27.73 | 7.2 | 1.44 | Upgrade
|
| Investment in Securities | 591.92 | 473.49 | 957.69 | -39.94 | -23.44 | -452.56 | Upgrade
|
| Other Investing Activities | -557.67 | -545.01 | -978.43 | 9.33 | 13.75 | 3.7 | Upgrade
|
| Investing Cash Flow | 27.53 | -94.22 | -80.24 | -146.97 | -207.96 | -673.56 | Upgrade
|
| Long-Term Debt Issued | - | 410.7 | 159.7 | 276.68 | 318.74 | 174.74 | Upgrade
|
| Total Debt Issued | 443.73 | 410.7 | 159.7 | 276.68 | 318.74 | 174.74 | Upgrade
|
| Long-Term Debt Repaid | - | -354.24 | -315.71 | -192.87 | -116.03 | -109.08 | Upgrade
|
| Total Debt Repaid | -438.16 | -354.24 | -315.71 | -192.87 | -116.03 | -109.08 | Upgrade
|
| Net Debt Issued (Repaid) | 5.57 | 56.46 | -156.01 | 83.81 | 202.71 | 65.66 | Upgrade
|
| Issuance of Common Stock | - | - | 84.1 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -179.49 | Upgrade
|
| Common Dividends Paid | -369.17 | -427.77 | -570.88 | -453.7 | -146.73 | -210.28 | Upgrade
|
| Other Financing Activities | -58.66 | 9.74 | -40 | 50 | -137.88 | -20 | Upgrade
|
| Financing Cash Flow | -422.27 | -361.57 | -682.78 | -319.89 | -81.9 | -344.1 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.77 | 0.86 | 8.31 | -2.71 | -1.13 | 0 | Upgrade
|
| Net Cash Flow | 167.32 | 94.32 | -226.04 | -59.33 | 307.01 | -549.38 | Upgrade
|
| Free Cash Flow | 499.47 | 472.85 | 466.4 | 266.15 | 392.52 | 242.14 | Upgrade
|
| Free Cash Flow Growth | 13.86% | 1.38% | 75.24% | -32.19% | 62.10% | -47.56% | Upgrade
|
| Free Cash Flow Margin | 24.41% | 21.77% | 23.80% | 15.29% | 25.06% | 14.76% | Upgrade
|
| Free Cash Flow Per Share | 0.85 | 0.81 | 0.79 | 0.46 | 0.68 | 0.41 | Upgrade
|
| Cash Income Tax Paid | 293.99 | 389.12 | 251.67 | 247.99 | 237.78 | 294.69 | Upgrade
|
| Levered Free Cash Flow | 416.19 | 350.91 | 249.38 | 156.13 | 351.23 | 82.53 | Upgrade
|
| Unlevered Free Cash Flow | 419.6 | 361.13 | 262.03 | 167.51 | 358.46 | 86.01 | Upgrade
|
| Change in Net Working Capital | -104.87 | 6.97 | 62.81 | 5.38 | -285.73 | 71.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.